



Lipid Management Readiness Checklist

SELF-ASSESSMENT TOOL

Evaluate your current policies, care practices and patient pathways for guideline directed secondary-prevention ASCVD care. The checklist below will allow you to assess gaps in care and opportunities for improvement when building and implementing your standardized lipid management plan.

These questions are designed to generate conversations with your internal teams to create a model for how your system will approach managing ASCVD patients.

-
- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Is there a clear referral and handoff process to get ASCVD patients seen by lipid management specialists after an acute event? | <input type="checkbox"/> What EMR reports do you have available to you to view LDL-C trends as a system, statin prescribing rates and post-acute ASCVD event follow up? |
| <input type="checkbox"/> Has staff been educated on current cholesterol guidelines ⁸ for secondary prevention of ASCVD? | <input type="checkbox"/> Is there an effective process for identifying patients who would benefit from more intensive lipid therapy? |
| <input type="checkbox"/> Does the lipid management plan development consider lifestyle modification, medication initiation and intensification and patient education? | <input type="checkbox"/> Are patient's baseline LDL-C levels measured and monitored regularly? What is your cadence for repeated testing for patients not at and at goal? |
| <input type="checkbox"/> Can shared management of ASCVD patients be improved, especially with primary care doctors and specialists? | <input type="checkbox"/> Is the role of statins and other lipid-lowering therapies in reducing ASCVD events understood by all prescribers? |
| <input type="checkbox"/> Are barriers to medication adherence and lifestyle changes assessed? | <input type="checkbox"/> What role could community resources play in managing ASCVD patients? |
| <input type="checkbox"/> What decision support tools and patient aids are used for shared decision making? | <input type="checkbox"/> Do you have a uniform goal of LDL-C < 70 mg/dL for secondary-prevention ASCVD patients in all clinics? |

⁸See Table 4.1